ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ESYN / options
ZSTK (25) COSM (29) NUS (50) MEDS (28) ⌘ Pro Terminal β†’

EnerSyn Global Inc. (ESYN) Options Positioning, Max Pain & Unusual Sweeps

$1.66 -5.14% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

EnerSyn Global Inc. (ESYN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $52.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ESYN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ESYN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, EnerSyn Global Inc. (NASDAQ: ESYN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.66 (-5.14% 1D, market cap $52.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ESYN compare to ZSTK and COSM in the Health Care sector?
β–Ό

Within the Health Care sector (Other Pharmaceuticals), ESYN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 53.0%, and ROIC of -35.0%. By comparison, ZSTK (ZeroStack Corp.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $60.7M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M). Among the 5-stock peer group, ESYN leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ESYN?
β–Ό

Per ESYN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001897245), EnerSyn Global Inc. generated $866.9K in revenue (-30.8% YoY), -$2.6M in net income, and -$1.8M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.64 (-1.12%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D+
Cash (7)Whales (7)SEC (11)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$3 Bull$2 Base$1 Bear
πŸ“¬ FREE ESYN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ESYN)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY ESYN SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime Γ— Technicals: 40% of 52W Range β€’ RSI-14 at 43.3 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
46
Grade D$2.03-5.9% Next Q
Q2 (-2Q)
43
Grade D$1.91-13.6% Next Q
Q3 (-1Q)
41
Grade D$1.65+0.6% Next Q
Current
38
Grade D-$1.66-7.8% Hist 90D Ξ±
Trajectory: D (46) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ESYN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ESYN currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.03) and Max Pain ($1.74) forces dealer call-delta covering toward $2.95.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ESYNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œESYN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ESYN)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ESYN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ESYN)

  • βœ“Walkthrough of ESYN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ESYN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +58.10%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.83H $1.83L $1.66C $1.66VOL 370
RES: $2.87SUP: $1.64SMA50: $2.03SMA200: $1.52
$2.92$2.39$1.87$1.34$0.82RES $2.87SUP $1.64$1.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ESYN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ESYN Butterfly Map β†’ + Track ESYN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -30.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ESYN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ESYN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ESYN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ESYN)

Health Care Rank #514 of 1016 βš”οΈ ZSTK vs ESYN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ESYN vs. ZSTK, COSM, NUS, MEDS)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, EnerSyn Global Inc. (ESYN) ranks #514 by composite RQD confidence (38/100, grade D-) and #740 by equity capitalization ($52.0M). Within this direct 5-issuer industry benchmark cohort, ESYN leads on earnings valuation at N/A trailing P/E, while NUS leads on capital efficiency and profitability with 6.7% ROIC and 69.4% gross margin. NUS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ESYN at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ESYN ACTIVE
EnerSyn Global Inc.
D- 38/100 β€” 53.0% -35.0% -5.14% $52.0M Benchmark Subject
ZSTK
ZeroStack Corp.
E 25/100 β€” 4.6% -35.0% -0.36% $60.7M /zstk-vs-esyn β†’
COSM
Cosmos Health Inc.
E 29/100 β€” 12.1% -35.0% +0.33% $31.0M /cosm-vs-esyn β†’
NUS
Nu Skin Enterprises Inc.
D 50/100 β€” 69.4% 6.7% +2.80% $226.3M /nus-vs-esyn β†’
MEDS
DataMeds AI Inc.
E 28/100 β€” -27.5% -35.0% -4.69% $9.3M /meds-vs-esyn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001897245

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EnerSyn Global Inc. (ESYN) reported GAAP revenue of $866.9K (-30.8% vs. FY2024 revenue of $1.3M , and +73120.1% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (+4.3% YoY). On the balance sheet, ESYN closed FY2025 with $4.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $866.9K -$2.6M -$1.8M -$1.8M $4.6M β€”
FY2024 (FY) 2024-12-31 $1.3M -$2.7M -$1.8M -$1.8M $6.4M β€”
FY2023 (FY) 2023-12-31 $1.2K -$1.1M -$2.6M -$2.6M β€” β€”

3. ESYN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ESYN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, EnerSyn Global Inc. (NASDAQ: ESYN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.66 (-5.14% 1D, market cap $52.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does ESYN compare to ZSTK and COSM in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), ESYN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 53.0%, and ROIC of -35.0%. By comparison, ZSTK (ZeroStack Corp.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $60.7M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M). Among the 5-stock peer group, ESYN leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ESYN?

Per ESYN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001897245), EnerSyn Global Inc. generated $866.9K in revenue (-30.8% YoY), -$2.6M in net income, and -$1.8M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ESYN trading relative to its 50-day, 200-day, and 52-week technical levels?

ESYN last traded at $1.66 (-5.14% on volume of 1,436 shares), positioning the stock -18.23% below its 50-day simple moving average ($2.03) and +9.21% above its 200-day simple moving average ($1.52). Across its 52-week range of $0.88 to $2.81, ESYN sits at the 40.4% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.45 to $1.87).

Direct Sub-Reports: ESYN RQD Cockpit ESYN 12M Forecast ESYN Earnings & Move ESYN Dividends & DRIP ESYN Insiders & 13F ESYN Whale Options ESYN Profit Sankey ESYN News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ESYN β€” EnerSyn Global Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

EnerSyn Global Inc. (ESYN) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.66 (-5.14% 1D, market capitalization $52.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 53.0%, operating margin of β€”, and free cash flow yield of -3.25%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

EnerSyn Global Inc. (ESYN) is a NASDAQ-listed issuer in the Health Care sector and the Other Pharmaceuticals industry. The profile does not describe its specific products, customers, or revenue model. Per the market data, the company reports a gross margin of 53%, which indicates the company retains a substantial share of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), EnerSyn Global Inc. (ESYN) reported $866.9K in annual revenue (up from $1.3M in FY2024, -30.8% YoY) and -$2.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2K revenue, -$1.1M net income) through FY2025, ESYN scaled operating cash flow to -$1.8M and free cash flow to -$1.8M, backed by $4.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.25% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.88 – $2.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain field is NONE, and the butterfly links list is empty. Upstream and downstream dependencies are β€” Sector correlation is limited to the Health Care sector and Other Pharmaceuticals industry classification. The liquidity signal describes a macro sensitivity rather than a named supply-chain relationship.

  • Key Question #1: Can ESYN sustain or expand its β€” operating margin and -35.0% ROIC against Other Pharmaceuticals peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $866.9K and free cash flow of -$1.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ESYN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ESYN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for EnerSyn Global Inc. (ESYN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ESYN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ESYN Bull vs. Bear Conversation Board β€” What's Your Call at $1.66?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ESYN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ESYN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $2.12 (+21.1%)
πŸ“Œ Pinned Debate

The Butterfly signal scores a BULLISH LIQUIDITY_TAILWIND at 94 severity, with a 96/100 macro tailwind score and a 6.00x net liquidity b

The Butterfly signal scores a BULLISH LIQUIDITY_TAILWIND at 94 severity, with a 96/100 macro tailwind score and a 6.00x net liquidity beta.. When you look under the hood at ESYN, Fundamental Cash Engine is 7/20 with 53.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $2.81. My 12M target is $2.12.

SectorRotator πŸ‚ BULL

@MidwestValue Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.75 and keeping dry powder in case we test $1.63.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $1.40 (-20.0%)
Spot @ $1.75

ROIC of -35%, a -3.25% FCF yield, and revenue falling from $1.3M to $0.9M show the cash engine is not yet self-funding.

Fading this rally in ESYN at $1.75. ROIC of -35%, a -3.25% FCF yield, and revenue falling from $1.3M to $0.9M show the cash engine is not yet self-funding.. With a beta of 1.0 and the stock sitting at $1.75 (52-wk range $0.88–$2.81), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%